PowderMed's Vaccines: Out of Chiron, Into the Clinic

The £542 million ($959 million) that Chiron Corp. spent acquiring PowderJect Pharmaceuticals PLC in mid-2003 was a move by the US company to get its hands on PowderJect's thriving Fluvirin influenza vaccine business and, oddly enough, bulk up its infrastructure on its home soil.